Johnson & Johnson (JNJ) is trading higher this morning after the FDA put its stamp of approval over the weekend for using company's blockbuster drug Remicade on pediatric patients with ulcerative colitis.
JNJ is currently up 0.72 to 62.31
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment